 |
|
|
| |
HBcrAg Decline in JNJ-56136379-treated Chronic
Hepatitis B Patients: Results of a Phase 1 Study
|
| |
| |
Reported by Jules Levin
EASL The International Liver Congress, Vienna, Austria, April 10-14, 2019
Oliver Lenz1, Thierry Verbinnen1, Moana Hodari1, Willem Talloen1, Joris Vandenbossche2, Umesh Shukla3, Françoise Berby4, Caroline Scholtes4,5,6, David Blue7, Jeysen Yogaratnam7, Sandra De Meyer1, Fabien Zoulim4,5,8
1Janssen Research & Development, Beerse, Belgium; 2Janssen Pharmaceuticals NV, Belgium; 3Janssen Pharmaceuticals Research & Development, Titusville, USA; 4INSERM U1052-Cancer Research Institute of Lyon, Lyon, France; 5University of Lyon, University Claude Bernard Lyon 1, Lyon, France; 6Department of Virology, Hospices Civils de Lyon, Lyon, France;
7Janssen Biopharma Inc., South San Francisco, CA, USA; 8Hepatology Unit, Hospices Civils de Lyon, Lyon, France
|
| |
|
|
|
|
|
